PAHC Phibro Animal Health Corporation
USHealthcareAs of 2026-07-10 11:54
Why PAHC matters now
Phibro Animal Health Corporation (PAHC) is a US stock in Healthcare. The latest InvestLog snapshot shows $32.72 with +1.03% on the session and $1.33B in market capitalization; recent performance reads 1-month -6.05% and YTD -14.75%.
The latest financial table shown here is Q3 2026, with revenue of $383.5M, net income of $24.0M, and EPS of $0.59. Investors can compare that operating picture with valuation signals such as P/E 24.50 and FCF yield 1.0%.
The latest indexable market news headline is "PAHC or LZAGY: Which Is the Better Value Stock Right Now?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $49.00; recent insider activity includes CORCORAN E THOMAS filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
24.50
PEG
0.07
P/B
3.57
P/S
0.86
EV/EBITDA
8.98
DCF Value
$-13.57
FCF Yield
1.0%
Div Yield
1.5%
Margins & Returns
Gross Margin
32.5%
Operating Margin
12.3%
Net Margin
6.3%
ROE
29.5%
ROA
6.6%
ROIC
11.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $383.5M | $24.0M | $0.59 |
| Q2 2026 | $373.9M | $27.5M | $0.67 |
| Q1 2026 | $363.9M | $26.5M | $0.65 |
| Q4 2025 | $378.7M | $17.2M | $0.42 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$49.00
Target (Median)
$49.00
Target Range
$49.00 - $49.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
0.46
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.